Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | WNT1 | P04628 | 4/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | CLK3 | P49761 | 2/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18379895 | 0.82 | GPR119 (0.45) | ESR2NAMPTWNT3A | |
| SCHEMBL20364262 | 0.72 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL18379975 | 0.71 | HDAC1 (0.61) | — | |
| SCHEMBL20364260 | 0.68 | ESR1 (0.44) | ESR1ESR2NAMPT | |
| SCHEMBL21037221 | 0.66 | QDPR (0.42) | WNT3A | |
| SCHEMBL20078111 | 0.66 | HDAC1 (0.47) | ESR1ESR2NAMPT | |
| SCHEMBL63979 | 0.66 | WNT3A (0.40) | DYRK1AGSK3BWNT1WNT3A | |
| SCHEMBL13490343 | 0.65 | P4HA1 (0.51) | NAMPTWNT3A | |
| SCHEMBL21037757 | 0.65 | SCN9A (0.41) | DYRK1AGSK3BWNT1 | |
| SCHEMBL22556107 | 0.65 | WNT3A (0.43) | DYRK1AGSK3BWNT1WNT3ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | ESR1 4856/4885ESR2 3923/4885NAMPT 2170/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | ESR1 4856/4885ESR2 3923/4885NAMPT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.